secwatch.observer — SEC 8-K summary
======================================

Issuer:     CymaBay Therapeutics, Inc. (—)
CIK:        0001042074
Form:       8-K
Filed at:   2024-03-22T23:59:59+00:00
Accession:  0001193125-24-074701
Event type: m_and_a
Sentiment:  neutral
Materiality: 1.00
Item codes: 2.01, 3.01, 3.03, 5.01, 5.02, 5.03, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Gilead completes acquisition of CymaBay for $32.50/share, ~$4.3B total
----------------------------------------------------------------------

- Tender offer expired with 77.3% of shares tendered; all conditions satisfied or waived.
- Merger effective March 22, 2024; CymaBay shareholders received $32.50 per share in cash.
- Aggregate consideration approximately $4.3 billion.
- Company becomes wholly owned subsidiary of Gilead; all prior directors and officers resigned.
- Shares to be delisted from Nasdaq and deregistered with SEC.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1042074/000119312524074701/0001193125-24-074701-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1042074/000119312524074701/d817708d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-074701

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer